



EUSA PHARMA APPOINTS CHIEF FINANCIAL OFFICER

Doylestown PA, USA and Oxford, UK - 18 March 2009 – EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, announced today the appointment of David Cook to the newly-created role of Chief Financial Officer. Mr Cook will split his time between EUSA's headquarters in the USA and the UK.

Mr Cook, who previously held the position of Finance Director at EUSA, has considerable expertise in financial management, business development and fund raising, developed during a career spanning nearly 20 years. Prior to joining the company, he was acting Chief Financial Officer for Zeneus Pharma, having been promoted from the role of Group Financial Controller. Previously, Mr Cook worked for PricewaterhouseCoopers for more than 10 years in a number of international roles in the UK and Australia, focusing on audit, transactional services and management consultancy. He holds a BA (Hons) degree in Chemistry from the University of Oxford and is a qualified chartered accountant.

"I want to warmly congratulate David on his appointment as Chief Financial Officer," said **Bryan Morton, Chief Executive of EUSA Pharma**. "The company has made tremendous progress since it was founded just over 2 years ago, having completed 4 major acquisitions and raising over \$275 million. David has made a significant contribution to that growth, taking ownership of many key business development activities in addition to managing EUSA's operational finances. David's appointment is particularly welcome as it marks a scaling up of EUSA's ambition to become one of the leading specialty companies in our field."

Commenting on his appointment, **David Cook, EUSA's Chief Financial Officer**, said, "Having completed the construction of a robust commercial infrastructure on both sides of the Atlantic, this is a tremendously exciting time for EUSA. Few companies have the unique combination of specialist medical and geographic focus that we have built, and I look forward to helping leverage that position in my new role as we continue our rapid progress towards becoming a major international business."

---ENDS---

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight marketed products, including Caphosol[®] for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Erwinase[®] and Kidrolase[®] for the treatment of acute lymphoblastic leukemia, Collatamp[®] G, a surgical implant impregnated with the antibiotic gentamicin, ProstaScint[®] for imaging the extent and spread of prostate cancer and Quadramet[®] for the treatment of pain in patients whose cancer has spread to the bones. EUSA also has several products in late-stage development.

Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, TVM Capital, NeoMed and NovaQuest. Since its foundation, the company has raised over \$275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Limited, the French biopharmaceutical company OPI SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. Key to its rapid growth strategy is the company's established commercial infrastructure in the US, pan-European presence covering over 20 countries and wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing, in line with its ambitious target to become the leading specialty company in its areas of therapeutic and geographic focus.

For more information please visit www.eusapharma.com.

Contacts

Bryan Morton
Chief Executive
EUSA Pharma
Tel: +44 (0)1865 784255

Rob Budge
RJB Communications
Tel: +44 (0)1865 760969
Mobile: +44 (0)7710 741241